BRPI0508464B8 - sulfonilpirróis, composição farmacêutica compreendendo os mesmos e uso dos mesmos - Google Patents

sulfonilpirróis, composição farmacêutica compreendendo os mesmos e uso dos mesmos

Info

Publication number
BRPI0508464B8
BRPI0508464B8 BRPI0508464A BRPI0508464A BRPI0508464B8 BR PI0508464 B8 BRPI0508464 B8 BR PI0508464B8 BR PI0508464 A BRPI0508464 A BR PI0508464A BR PI0508464 A BRPI0508464 A BR PI0508464A BR PI0508464 B8 BRPI0508464 B8 BR PI0508464B8
Authority
BR
Brazil
Prior art keywords
sulfonylpyrroles
pharmaceutical composition
novel
compounds
relates
Prior art date
Application number
BRPI0508464A
Other languages
English (en)
Portuguese (pt)
Inventor
Dullweber Frank
Vennemann Matthias
Gimmnich Petra
Baer Thomas
Beckers Thomas
Maier Thomas
Original Assignee
Altana Pharma Ag
Nycomed Gmbh
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag, Nycomed Gmbh, Takeda Gmbh filed Critical Altana Pharma Ag
Publication of BRPI0508464A publication Critical patent/BRPI0508464A/pt
Publication of BRPI0508464B1 publication Critical patent/BRPI0508464B1/pt
Publication of BRPI0508464B8 publication Critical patent/BRPI0508464B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
BRPI0508464A 2004-03-11 2005-03-10 sulfonilpirróis, composição farmacêutica compreendendo os mesmos e uso dos mesmos BRPI0508464B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04101003.4 2004-03-11
EP04101003 2004-03-11
PCT/EP2005/051086 WO2005087724A2 (en) 2004-03-11 2005-03-10 Sulphonylpyrroles as hdac inhibitors

Publications (3)

Publication Number Publication Date
BRPI0508464A BRPI0508464A (pt) 2007-07-31
BRPI0508464B1 BRPI0508464B1 (pt) 2020-02-11
BRPI0508464B8 true BRPI0508464B8 (pt) 2021-05-25

Family

ID=34928899

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508464A BRPI0508464B8 (pt) 2004-03-11 2005-03-10 sulfonilpirróis, composição farmacêutica compreendendo os mesmos e uso dos mesmos

Country Status (25)

Country Link
US (5) US7842820B2 (enExample)
EP (2) EP1725528B1 (enExample)
JP (1) JP4856623B2 (enExample)
KR (1) KR101130556B1 (enExample)
CN (1) CN1926103B (enExample)
AR (1) AR048427A1 (enExample)
AU (1) AU2005221834B2 (enExample)
BR (1) BRPI0508464B8 (enExample)
CA (1) CA2558552C (enExample)
CY (1) CY1114284T1 (enExample)
DK (1) DK1725528T3 (enExample)
EA (1) EA012451B1 (enExample)
ES (1) ES2430371T3 (enExample)
HR (1) HRP20130810T1 (enExample)
IL (1) IL177168A (enExample)
ME (1) ME02122B (enExample)
NO (1) NO337457B1 (enExample)
NZ (1) NZ549251A (enExample)
PL (1) PL1725528T3 (enExample)
PT (1) PT1725528E (enExample)
RS (1) RS52937B (enExample)
SI (1) SI1725528T1 (enExample)
TW (1) TWI353977B (enExample)
WO (1) WO2005087724A2 (enExample)
ZA (1) ZA200606315B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1651612T3 (pl) 2003-07-22 2012-09-28 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
EP1725528B1 (en) * 2004-03-11 2013-05-29 4Sc Ag Sulphonylpyrroles as hdac inhibitors
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
AU2006207325B2 (en) * 2005-01-21 2012-08-16 Astex Therapeutics Limited Pharmaceutical compounds
WO2006097474A1 (en) * 2005-03-15 2006-09-21 Nycomed Gmbh N-sulphonylpyrroles and their use as histone deacetylase inhibitors
EP1868994B1 (en) * 2005-04-07 2011-05-25 4Sc Ag Sulfonylpyrroles as histone deacetylase inhibitors
NZ541788A (en) * 2005-08-11 2007-12-21 Auckland Uniservices Ltd Conducting polymers and their use in oligonucleotide (ODN) probes
AU2006298881A1 (en) * 2005-09-21 2007-04-12 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
ATE549333T1 (de) * 2005-09-21 2012-03-15 4Sc Ag Neue sulfonylpyrrole als hdac-inhibitoren
CA2635392C (en) * 2005-12-27 2013-07-23 Universidad Del Pais Vasco - Euskal Herriko Unibertsitatea New pyrrolic derivatives with histone deacetylase inhibitory activity
EP2100878A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Novel method for the production of sulphonylpyrroles as HDAC inhibitors
EP2100882A1 (en) * 2008-03-12 2009-09-16 4Sc Ag (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts
US8680113B2 (en) * 2008-07-01 2014-03-25 Ptc Therapeutics, Inc. BMI-1 protein expression modulators
ES2620027T3 (es) 2008-09-03 2017-06-27 Biomarin Pharmaceutical Inc. Composiciones que incluyen derivados del ácido 6-aminohexanoico como inhibidores de HDAC
CN101941948A (zh) * 2009-07-10 2011-01-12 南开大学 点击化学合成具有分支结构的组蛋白去乙酰酶抑制剂
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CA2828524C (en) 2011-02-28 2020-01-07 Repligen Corporation Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
BR112015023399A8 (pt) 2013-03-15 2019-12-03 Biomarin Pharm Inc inibidores de hdac, seu uso e composição farmacêutica
EP3769757A3 (en) * 2013-10-18 2021-10-06 The General Hospital Corporation Imaging histone deacetylases with a radiotracer using positron emission tomography
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
CN105801464B (zh) * 2014-12-29 2019-05-28 成都先导药物开发有限公司 吡咯酰胺类化合物及其制备方法与用途
WO2017178577A1 (en) 2016-04-14 2017-10-19 4Sc Ag Medical application of resminostat in asian patients
TW201912183A (zh) 2017-08-31 2019-04-01 德商４Ｓｃ製藥公司 Hdac抑制劑與抗代謝藥劑組合用於癌症治療
TW202011959A (zh) 2018-04-14 2020-04-01 美商戴納瓦克斯技術公司 用於治療癌症之包括CpG-C 型寡核苷酸及組蛋白去乙醯酶抑制劑之組合
KR20200143452A (ko) 2018-04-17 2020-12-23 4에스체 악티엔게젤샤프트 암 치료를 위한 hdac 억제제, lag-3 억제제 및 pd-1 억제제 또는 pd-l1 억제제를 포함하는 배합물
TW202114659A (zh) 2019-10-02 2021-04-16 德商４Ｓｃ製藥公司 用於癌症治療之含ｈｄａｃ抑制劑、ｃｔｌａ—４抑制劑及ｐｄ—１抑制劑或ｐｄ—ｌ１抑制劑之組合

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960787A (en) 1989-02-06 1990-10-02 Ciba-Geigy Corporation Certain pyrrolyl-substituted hydroxamic acid derivatives
DK0570594T3 (enExample) 1991-12-10 1997-08-25 Shionogi & Co
CA2223154A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
JP2003514905A (ja) 1999-11-23 2003-04-22 メルク エンド カムパニー インコーポレーテッド ピラジノン系トロンビン阻害薬
EP1748046A3 (en) * 1999-11-23 2007-08-22 Methylgene, Inc. Inhibitors of histone deacetylase
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
NZ541950A (en) 2001-08-09 2007-02-23 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
CN101851173A (zh) 2001-09-14 2010-10-06 梅特希尔基因公司 组蛋白脱乙酰化酶抑制剂
US7205304B2 (en) * 2002-03-13 2007-04-17 Janssen Pharmaceutica N.V. Sulfonyl-Derivatives as novel inhibitors of histone deacetylase
EP1539675B1 (en) 2002-08-29 2013-11-06 Temple University - Of The Commonwealth System of Higher Education Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof
GB0226855D0 (en) 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
US8362017B2 (en) 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
US20080242681A1 (en) 2004-01-22 2008-10-02 Altana Pharma Ag N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors
US20050197336A1 (en) 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
EP1725528B1 (en) * 2004-03-11 2013-05-29 4Sc Ag Sulphonylpyrroles as hdac inhibitors
US7345043B2 (en) 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
GB2415703A (en) 2004-07-02 2006-01-04 Hewlett Packard Development Co Liquid crystal display device
UA87884C2 (uk) 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
US7432808B2 (en) 2004-12-15 2008-10-07 Intel Corporation Wireless module enabled component carrier for parts inventory and tracking
ATE496892T1 (de) 2004-12-17 2011-02-15 Janssen Pharmaceutica Nv Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
WO2006097474A1 (en) 2005-03-15 2006-09-21 Nycomed Gmbh N-sulphonylpyrroles and their use as histone deacetylase inhibitors
EP1868994B1 (en) * 2005-04-07 2011-05-25 4Sc Ag Sulfonylpyrroles as histone deacetylase inhibitors
AU2006298881A1 (en) * 2005-09-21 2007-04-12 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
ATE549333T1 (de) 2005-09-21 2012-03-15 4Sc Ag Neue sulfonylpyrrole als hdac-inhibitoren
EP2060565A1 (en) * 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
EP2100882A1 (en) * 2008-03-12 2009-09-16 4Sc Ag (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts

Also Published As

Publication number Publication date
IL177168A (en) 2012-03-29
HK1102583A1 (en) 2007-11-30
TWI353977B (en) 2011-12-11
JP4856623B2 (ja) 2012-01-18
CN1926103A (zh) 2007-03-07
US20100261761A1 (en) 2010-10-14
EP1725528A2 (en) 2006-11-29
ZA200606315B (en) 2008-02-27
EA012451B1 (ru) 2009-10-30
EP2272827A1 (en) 2011-01-12
KR101130556B1 (ko) 2012-03-30
US20100261721A1 (en) 2010-10-14
US8067615B2 (en) 2011-11-29
IL177168A0 (en) 2006-12-10
CN1926103B (zh) 2012-12-19
CA2558552C (en) 2015-06-02
NO337457B1 (no) 2016-04-18
WO2005087724A2 (en) 2005-09-22
AU2005221834B2 (en) 2010-09-30
US20130079347A1 (en) 2013-03-28
US7842820B2 (en) 2010-11-30
ES2430371T3 (es) 2013-11-20
JP2007527902A (ja) 2007-10-04
US8399505B2 (en) 2013-03-19
KR20060131927A (ko) 2006-12-20
CY1114284T1 (el) 2016-08-31
NO20064418L (no) 2006-12-08
PT1725528E (pt) 2013-09-26
NZ549251A (en) 2010-05-28
DK1725528T3 (da) 2013-09-02
CA2558552A1 (en) 2005-09-22
WO2005087724A3 (en) 2005-12-08
EP1725528B1 (en) 2013-05-29
ME02122B (me) 2014-02-28
AU2005221834A1 (en) 2005-09-22
BRPI0508464B1 (pt) 2020-02-11
SI1725528T1 (sl) 2013-11-29
BRPI0508464A (pt) 2007-07-31
TW200538432A (en) 2005-12-01
US8969401B2 (en) 2015-03-03
PL1725528T3 (pl) 2013-12-31
EA200601587A1 (ru) 2007-04-27
AR048427A1 (es) 2006-04-26
HRP20130810T1 (en) 2013-09-30
RS52937B (sr) 2014-02-28
US20110166140A1 (en) 2011-07-07
US20070184979A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
BRPI0508464B8 (pt) sulfonilpirróis, composição farmacêutica compreendendo os mesmos e uso dos mesmos
EA201100689A1 (ru) N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
NO20071127L (no) Triazoloftalaziner
CL2009000323A1 (es) Compuestos derivados de heterociclos no condensados sustituidos, inhibidores de la funcion de la proteina ns5a; composicion farmaceutica que los comprende; y su uso para tratar la infeccion del virus de la hepatitis c.
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
EA200700189A1 (ru) Производные хиназолина в качестве ингибиторов parp
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
EA201070278A1 (ru) Ингибиторы гамма-секретазы
BR112012017269A2 (pt) compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos
EA200700185A1 (ru) Производные хиназолиндиона в качестве ингибиторов parp
ECSP077335A (es) Inhibidores de la interaccion entre mdm2 y p53
EA201070247A1 (ru) Ингибиторы протеасом
CY1107817T1 (el) Καρβοξαμιδια θειοφαινιου ως αναστολεις του ενζυμου ικκ-2
ATE432272T1 (de) Aminophenylderivate als neue inhibitoren von histondeacetylase
EA200901124A1 (ru) Соединения формулы (i) в качестве ингибиторов серинпротеазы
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
SE0303541D0 (sv) New compounds
EA201000494A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
ATE513818T1 (de) Chinazolinonderivate als tubulinpolymerisationshemmer
CY1111432T1 (el) Τετραϋδροκινολινες για χρηση ως διαμορφωτες της μιτοτικης κινητικης πρωτεϊνης eg5
DE502007005636D1 (de) Triaza-benzoäeüazulenderivate zur behandlung von tumoren
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
BRPI0508471A8 (pt) compostos de hidróxi-6-fenilfenantidinas substituídas por difluoroetóxi, composição farmacêutica e uso para a produção dos mesmos
ATE455095T1 (de) Vanilloidrezeptor trpv1-antagonisten
BRPI0607241A2 (pt) derivados de fenil metanona e o uso dos mesmos como inibidores do transportador de glicina 1

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NYCOMED GMBH (DE)

Free format text: NOME ALTERADO DE: ALTANA PHARMA AG

B25D Requested change of name of applicant approved

Owner name: TAKEDA GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/03/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: 4SC AG (DE)